New Drug appproved in Europe for type two diabeties

Brystol-Myers Squibb and AstraZeneca announced yesterday their drug, ONGLYZA®, has been approved for use in Europe as a combination therapy for type two diabetes.  Data from the 24 week trial and the 28 week tiral extension were presented in June 2011 and September 2011, respectively. ONGLYZA® was proven, in a Phase 3b 24 week trial, to be effective in reducing blood sugar levels in patients with type two diabetes. When compared with the placebo in the 28-week extension period of the study, ONGLYZA® 5 mg added to insulin maintained reductions of HbA1c from 24 to 52 weeks. As effective as it is, ONGLYZA® is not intended for independent use. It is intended to be combined with metformin, sulphonylurea, thiazolidinedione, or insulin when these treatments--combined with diet and exercise--are insufficient.

SOURCE: Bristol-Myers Squibb Company Press Release